exploring direct target genes of HDAC inhibitor for epigenomic evidenced based medicine

Research Project

Project/Area Number	15K18441
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Tumor therapeutics
Research Institution	Tokyo Medical and Dental University
Principal Investigator	Tanimoto Kousuke 東京医科歯科大学, 難治疾患研究所, 助教 (60611613)
Project Period (FY)	2015-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000) Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywords	ヒストン脱アセチル化酵素阻害剤 / ヒストンアセチル化 / HDAC阻害剤 / エピゲノム
Outline of Final Research Achievements	H3 acetylation profiles of Jurkat cell line with and without HDAC (histone deacetylase) inhibitor SAHA (Vorinostat) treatment were analyzed by ChIP-seq. Integrated analysis of H3 acetylation profile and gene expression profile revealed that only 7 % genes were acetylated among up-regulated genes by SAHA treatment. This result suggested that exploring direct target of HDAC inhibitor require not only gene expression analysis but also histone acetylation analysis.